Search
EHA Ranking 2025
The information on this page is also available as a printable PDF. EHA Ranking 2025 — PDF version
Position
Company
Priority points
Corporate Level
1
Johnson & Johnson
1. 488,82
Platinum
2
Bristol Myers Squibb
1.
EHA Research Conference 2025
Dates: March 17-20, 2025
Location: Málaga, Spain
Chairs: Alba Maiques Diaz, Ruud Delwel, Panagiotis Ntziachristos, Marcus Buschbeck, Mark Dawson,
Özgen Deniz, Kimberly Stegmaier, and Nina Cabezas Wallscheid
Registration is now open
EHA is proud to announce the third edition of the EHA Research Conference, titled "Transcriptional control and chromatin alterations in normal and abnormal hematopoiesis".…
National Society Day 2025
Presentations from the National Society Days held by EHA on February 13 and 14, 2025.
Read moreDates and deadlines
You may find in this page all the dates and deadlines related to the EHA2025 Congress. All deadlines, except if mentioned differently, end at 23:59 CET/CEST.
The timelines will be updated regularly.
Research training documents for scholars
CBTH documentsCBTH Non-disclosure Agreement
CRTH documentsCRTH Conditions of Acceptance and Participation
CRTH Non-disclosure Agreement
TRTH documentsTRTH Non-disclosure Agreement
SWG Grant-funded projects, 2025
In November and December 2024, SWGs were invited to develop project ideas and apply for a 2025 SWG Grant. For the 2025 call, EHA offered five grants, each worth €30,000.
Read moreSession information—May 15, 2025
Topic'Optimizing vaccination strategies for chemotherapy patients: Bridging gaps in preventive care. '
Speaker detailsVerena PetzerSince February 2025, Dr Verena Petzer has been a specialist in internal medicine for hematology and oncology at the Medical University of Innsbruck in Austria.
Session information—April 22, 2025
Topic'Respiratory viral infections in hematological patients. '
Speaker detailsJon Salmanton-GarcíaJon Salmanton-García (Sodupe, 1990) is a postdoctoral researcher at University Hospital Cologne, Germany, specializing in studying and managing fungal and respiratory infections, particularly in immunocompromised patients.